目的探讨ｒａｓｐ２１与ＧＳＴｐｉ在子宫内膜癌发生、发展过程中的表达状态及意义。方法用免疫组化ＬＳＡＢ法对３２例子宫内膜腺癌和１２例子宫内膜增生过长组织进行检测，观察ｒａｓｐ２１和ＧＳＴｐｉ在病变组织中的分布。结果３２例子宫内膜癌中ｒａｓｐ２１、ＧＳＴｐｉ阳性率分别为６５．６％（２１／３２）和７１．９％（２３／３２）；１２例子宫内膜增生过长组织中的ｒａｓｐ２１，ＧＳＴｐｉ阳性率分别为１６．７％（２／１２）和３３．３％（４／１２）。ｒａｓｐ２１，ＧＳＴｐｉ在癌组织中的表达均高于子宫内膜增生过长（Ｐ＜０．０１；Ｐ＜０．０５）。结论ｒａｓｐ２１和ＧＳＴｐｉ均与子宫内膜癌的发生发展有关，两种标记物在子宫内膜高、中分化癌及癌前病变中的表达有协同作用，可作为子宫内膜癌早期诊断的参考指标 Objective To investigate the expression status and significance of rasp21 and GSTpi in the occurrence and development of endometrial carcinoma. Methods 32 cases of endometrial adenocarcinoma and 12 cases of endometrial hyperplasia were detected by immunohistochemical LSAB method. The distribution of rasp21 and GST-pi in the lesions was observed. Results The positive rates of rasp21 and GST-pi in 32 cases of endometrial carcinoma were 65.6% (21/32) and 71.9% (23/32), respectively; rasp21 was found in 12 cases of endometrial hyperplasia. The positive rate of GST-pi was 16.7% (2/12) and 33.3% (4/12), respectively. The expression of rasp21 and GST-pi in cancer tissue was higher than that in endometrial hyperplasia (P<0.01; P<0.05). Conclusions Both rasp21 and GSTpi are associated with the occurrence and development of endometrial carcinoma. The two markers have a synergistic effect on the expression of high and middle differentiated carcinoma and precancerous lesions of the endometrium. It can be used as an early diagnosis of endometrial carcinoma. reference indicator